EA201171292A1 - Короткоцепочечные пептиды в качестве агониста рецептора паратиреоидного гормона (pth) - Google Patents
Короткоцепочечные пептиды в качестве агониста рецептора паратиреоидного гормона (pth)Info
- Publication number
- EA201171292A1 EA201171292A1 EA201171292A EA201171292A EA201171292A1 EA 201171292 A1 EA201171292 A1 EA 201171292A1 EA 201171292 A EA201171292 A EA 201171292A EA 201171292 A EA201171292 A EA 201171292A EA 201171292 A1 EA201171292 A1 EA 201171292A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- short
- pth
- chain peptides
- peptides
- vitro
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000000556 agonist Substances 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 238000000338 in vitro Methods 0.000 abstract 2
- 208000000038 Hypoparathyroidism Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 102100036893 Parathyroid hormone Human genes 0.000 abstract 1
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 1
- 229940116372 Parathyroid hormone receptor agonist Drugs 0.000 abstract 1
- 102000057297 Pepsin A Human genes 0.000 abstract 1
- 108090000284 Pepsin A Proteins 0.000 abstract 1
- 101710191547 Peptidyl-tRNA hydrolase 1 Proteins 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 230000010478 bone regeneration Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001853 liver microsome Anatomy 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 229940111202 pepsin Drugs 0.000 abstract 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000006337 proteolytic cleavage Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение предоставляет новые короткоцепочечные пептиды, которые действуют, главным образом, как агонист рецептора паратиреоидного гормона (РТН/РТН-1). Указанные короткоцепочечные пептиды проявляют повышенную устойчивость к протеолитическому расщеплению. Обнаружено, что большинство короткоцепочечных пептидов оставались стабильными в плазме крови крысы в течение 24 часов (in vitro), проявляли повышенную устойчивость к действию ферментов GIT, таких как пепсин и кислое значение рН желудка, а также к действию микросом печени (in vitro). Благодаря повышенной метаболической устойчивости, не говоря о парентеральном способе введения, некоторые из короткоцепочечных пептидов также могут быть введены пероральными способами введения для лечения/профилактики гипопаратиреоза и заболеваний, характеризующихся уменьшением костной массы, таких как остеопороз, постменопаузальный остеопороз, и для стимуляции регенерации кости. A-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-Z-B.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1095MU2009 | 2009-04-24 | ||
| IN225MU2010 | 2010-01-28 | ||
| PCT/IN2010/000264 WO2010128521A2 (en) | 2009-04-24 | 2010-04-26 | Short-chain peptides as parathyroid hormone (pth) receptor agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201171292A1 true EA201171292A1 (ru) | 2012-05-30 |
| EA022212B1 EA022212B1 (ru) | 2015-11-30 |
Family
ID=43050579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201171292A EA022212B1 (ru) | 2009-04-24 | 2010-04-26 | Короткоцепочечные пептиды в качестве агониста рецептора паратиреоидного гормона (pth) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8383581B2 (ru) |
| EP (1) | EP2421893A2 (ru) |
| JP (1) | JP5744844B2 (ru) |
| KR (1) | KR101451470B1 (ru) |
| CN (1) | CN102405229A (ru) |
| AU (1) | AU2010245642A1 (ru) |
| BR (1) | BRPI1008103A2 (ru) |
| CA (1) | CA2757874C (ru) |
| EA (1) | EA022212B1 (ru) |
| IL (1) | IL215625A (ru) |
| MX (1) | MX2011010968A (ru) |
| NZ (1) | NZ595437A (ru) |
| SG (1) | SG174532A1 (ru) |
| WO (1) | WO2010128521A2 (ru) |
| ZA (1) | ZA201107078B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3928487A (en) * | 1974-11-27 | 1975-12-23 | Standard Oil Co | Alkylation process utilizing hydrofluoric acid with a minor amount of fluorosulfuric acid |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| SG191759A1 (en) | 2010-12-30 | 2013-08-30 | Enanta Pharm Inc | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| WO2012120532A2 (en) | 2011-02-02 | 2012-09-13 | Cadila Healthcare Limited | Cyclic short chain peptides |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4486256B2 (ja) | 1998-10-22 | 2010-06-23 | ザ・ジェネラル・ホスピタル・コーポレイション | 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体 |
| WO2001023427A1 (en) * | 1999-09-29 | 2001-04-05 | The General Hospital Corporation | Polypeptide derivatives of parathyroid hormone (pth) |
| AU7734800A (en) * | 1999-09-29 | 2001-04-30 | General Hospital Corporation, The | Polypeptide derivatives of parathyroid hormone (pth) |
| EP1439854B1 (en) | 2001-07-23 | 2016-12-14 | The General Hospital Corporation | Conformationally constrained parathyroid hormone (pth) analogs |
| AU2002951372A0 (en) | 2002-09-13 | 2002-09-26 | St Vincent's Institute Of Medical Research | Parathyroid hormone-like polypeptides |
| EP1592434A4 (en) * | 2003-01-24 | 2009-07-01 | Gen Hospital Corp | PARATHORMONE ANALYSIS (PTH) WITH CONFORMATIONAL CONSTRAINTS WITH LACTAME BRIDGES |
| US7795220B2 (en) | 2003-03-19 | 2010-09-14 | The General Hospital Corporation | Conformationally constrained parathyroid hormones with alpha-helix stabilizers |
| US7910544B2 (en) | 2003-07-17 | 2011-03-22 | The General Hospital Corporation | Conformationally constrained parthyroid hormone (PTH) analogs |
| WO2005077918A1 (en) | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| US20070099940A1 (en) | 2004-02-11 | 2007-05-03 | Spearing Paul K | Pth agonists |
| ITMI20041440A1 (it) | 2004-07-19 | 2004-10-19 | Abiogen Pharma Spa | Peptidi analoghi del pth-1-11 |
| JP2009508820A (ja) | 2005-09-06 | 2009-03-05 | ゼロス セラピューティクス， インコーポレイテッド | 副甲状腺ホルモンアナログおよび使用法 |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| RU2506274C2 (ru) * | 2007-08-01 | 2014-02-10 | Дзе Дженерал Хоспитал Корпорейшн | Способы скрининга с применением g-белок сопряженных рецепторов и родственных композиций |
-
2010
- 2010-04-26 EA EA201171292A patent/EA022212B1/ru not_active IP Right Cessation
- 2010-04-26 SG SG2011068863A patent/SG174532A1/en unknown
- 2010-04-26 NZ NZ595437A patent/NZ595437A/en not_active IP Right Cessation
- 2010-04-26 WO PCT/IN2010/000264 patent/WO2010128521A2/en active Application Filing
- 2010-04-26 BR BRPI1008103A patent/BRPI1008103A2/pt not_active IP Right Cessation
- 2010-04-26 MX MX2011010968A patent/MX2011010968A/es active IP Right Grant
- 2010-04-26 EP EP10747683.0A patent/EP2421893A2/en not_active Withdrawn
- 2010-04-26 CN CN2010800175792A patent/CN102405229A/zh active Pending
- 2010-04-26 KR KR1020117026057A patent/KR101451470B1/ko not_active IP Right Cessation
- 2010-04-26 CA CA2757874A patent/CA2757874C/en not_active Expired - Fee Related
- 2010-04-26 JP JP2012506651A patent/JP5744844B2/ja not_active Expired - Fee Related
- 2010-04-26 AU AU2010245642A patent/AU2010245642A1/en not_active Abandoned
- 2010-04-26 US US13/259,706 patent/US8383581B2/en not_active Expired - Fee Related
-
2011
- 2011-09-28 ZA ZA2011/07078A patent/ZA201107078B/en unknown
- 2011-10-09 IL IL215625A patent/IL215625A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2757874C (en) | 2016-02-16 |
| US20120108496A1 (en) | 2012-05-03 |
| NZ595437A (en) | 2014-03-28 |
| IL215625A0 (en) | 2012-01-31 |
| SG174532A1 (en) | 2011-10-28 |
| JP2012524775A (ja) | 2012-10-18 |
| JP5744844B2 (ja) | 2015-07-08 |
| MX2011010968A (es) | 2012-01-19 |
| KR101451470B1 (ko) | 2014-10-15 |
| EA022212B1 (ru) | 2015-11-30 |
| KR20120034606A (ko) | 2012-04-12 |
| CA2757874A1 (en) | 2010-11-11 |
| US8383581B2 (en) | 2013-02-26 |
| WO2010128521A2 (en) | 2010-11-11 |
| ZA201107078B (en) | 2014-03-26 |
| BRPI1008103A2 (pt) | 2016-05-03 |
| EP2421893A2 (en) | 2012-02-29 |
| CN102405229A (zh) | 2012-04-04 |
| IL215625A (en) | 2016-12-29 |
| WO2010128521A3 (en) | 2011-03-10 |
| AU2010245642A1 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201171292A1 (ru) | Короткоцепочечные пептиды в качестве агониста рецептора паратиреоидного гормона (pth) | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| EA201391756A1 (ru) | Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами | |
| HK1088840A1 (en) | Stable analogs of glp-1 glp-1 | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| NZ603445A (en) | Gip-based mixed agonists for treatment of metabolic disorders and obesity | |
| PE20091221A1 (es) | Anticuerpos recombinantes contra la esclerostina | |
| BR112013027153A2 (pt) | método de aplicação de fármaco para pth, pthrp e peptídeos relacionados | |
| MA33826B1 (fr) | Analogue du peptide d'oxyntomoduline | |
| GEP20176629B (en) | Glucagon/glp-1 receptor co-agonists | |
| IL245906A0 (en) | Peptide analogs of melanocyte-stimulating hormone alpha | |
| AR067972A1 (es) | Composiciones de fenilalaninamoniacoliasa de procariontes y uso de sus composiciones en metodos para tratar cancer | |
| UA96441C2 (ru) | Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением | |
| EA201100038A1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| WO2010085700A3 (en) | Treatment for obesity | |
| MY167804A (en) | Treatment of degenerative joint disease | |
| UA109949C2 (uk) | Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання | |
| EA201391387A1 (ru) | Нейропротекторные пептиды | |
| MX2012007416A (es) | Composiciones y metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis. | |
| RU2014122171A (ru) | Пептидные аналоги для лечения заболеваний и расстройств | |
| BRPI0821467B8 (pt) | composição de furina recombinante, método para produzir a composição de furina recombinante, e, método para produzir uma proteína madura utilizando a composição de furina recombinante | |
| EA201591165A1 (ru) | Стабилизированные полипептиды инсулиноподобного фактора роста | |
| WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
| NZ590469A (en) | Treatment of rheumatoid arthritis with human beta defensins (1-4) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |